Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study

BACKGROUND: Razumab™ (world’s first biosimilar ranibizumab) is approved for several macular disorders including wet age-related macular degeneration (AMD). We evaluated the safety and efficacy of biosimilar ranibizumab in wet AMD. METHODS: This prospective, multicentre, rAnibizumab bioSimilar Safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Shashikant, Gupta, Vishali, Maiti, Aniruddha, Natesh, Sribhargava, Saxena, Sandeep, Dave, Vivek, Parmar, Vimal, Sampangi, Raju, Murthy, Hemanth, Dharwadkar, Sandhya, Yadav, Naresh Kumar, Joshi, Shrinivas, Mayor, Rahul, Ratra, Dhanashree, Basu, Soumyava, Goel, Neha, Chaturvedi, Alok, Patel, Ronak, Jose, Vinu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992797/
https://www.ncbi.nlm.nih.gov/pubmed/33762008
http://dx.doi.org/10.1186/s40942-021-00293-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992797/
https://www.ncbi.nlm.nih.gov/pubmed/33762008
http://dx.doi.org/10.1186/s40942-021-00293-w

Ejemplares similares